CLRBCellectar Biosciences, Inc.
2.590USD-1.15%Mkt Cap: 24.48M $P/E: —3d ago
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid d…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript Phase 3 trial underway for iopofosine I 131 in Waldenstrom's macroglobulinemia. | ||
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ... Company reports 79.2% major response rate in high-risk WM patients and secures up to $140 million to support NDA submission and pipeline expansion. | ||
 Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary Moby summary of Cellectar Biosciences, Inc.'s Q2 2026 earnings call | ||